Command Palette

Search for a command to run...

MOREPENLAB

53.85-0.26%
Market Cap
₹2,639.49 Cr
Stock P/E
25.99
ROCE
16.82%
ROE
12.08%
Book Value
₹16.58

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

Financials

YoY Net Sales
EPS Growth
Operating Margin

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Morepen Laboratories Ltd. shows moderate growth and strong financial health compared to its peers. While it has the lowest debt levels, its profitability metrics are lower than those of top performers in the sector. Companies like Cipla and Dr. Reddy's Laboratories exhibit superior profitability and growth, positioning them as sector leaders, while Divi's Laboratories and Sun Pharmaceutical Industries appear overvalued given their high PE ratios.

Key Points
  • Morepen Laboratories has low debt levels (0.0342) compared to peers.
  • Cipla and Dr. Reddy's have the highest profitability metrics with ROE of 16.63% and 21.76% respectively.
  • Divi's Laboratories shows negative revenue growth over three years, indicating financial weakness.
Top Performers
Cipla Ltd.

Highest ROE (16.63%) and significant revenue growth (YoY 13.28%).

Dr. Reddy's Laboratories Ltd.

Strong profitability with an ROE of 21.76% and high growth trajectory.

Mankind Pharma Ltd.

Outstanding revenue growth of 18.12% YoY and strong profitability metrics.